ArticleDermatology and therapy2026
Urticaria Voices: Perspectives of Dermatologists and Allergists Regarding Chronic Urticaria Care and Its Treatment in China.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic urticaria (CU) causes recurrent itchy wheals (hives), angioedema, or both for > 6 weeks, classified as chronic spontaneous urticaria (CSU) or chronic inducible urticaria (CIndU) based on identifiable trigger presence. China ranks second globally in disability-adjusted life years for urticaria, calling for tailored interventions. This study investigated perceptions of Chinese dermatologists and allergists regarding the disease burden and management in patients with CU.
methodsA cross-sectional online survey (40 min) was conducted among 265 specialists (81% dermatologists, 19% allergists) across China. Eligible physicians had autonomous prescribing authority for all CU treatments including biologics, and active CSU/CIndU caseloads. Participants recalled patient characteristics, burden across life domains, and treatment patterns.
resultsPhysicians reported that patients consulted a mean of four specialists before diagnosis. At initial assessment, 25% presented with severe/very severe symptoms. Currently, 19% of patients with CSU and 18% with CIndU have inadequately controlled disease (urticaria control test [UCT] < 12). Among these patients, physicians reported substantial burden: 7/10 for mental/emotional and financial domains and 6/10 for social relationships (10 = extreme negative impact). Overall, 61% were assessed as moderately impaired in achieving full life potential. Sleep disturbances affected 44% of all patients with CU. While 93% of physicians prioritize complete symptom control, they believe this is achievable in 59% of patients. Physicians attempt a mean of three antihistamine switches before biologic escalation.
conclusionsDespite recalling ~20% inadequate disease control rates, physicians recognize substantial burden with most patients impaired in achieving life potential. The gap between treatment goals and perceived achievability, combined with diagnostic delays and conservative escalation patterns, highlights opportunities for comprehensive CU management in China.
Indexed as
Identifiers
42839190What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.